PARP Inhibitors in Breast Cancer: a Short Communication

期刊论文
出版模式：

开放获取
发表日期：

2024年1月2日

查看全文

Gordon R. Daly,
Maen Monketh AlRawashdeh,
Jason McGrath,
Gavin P. Dowling,
Luke Cox,
Sindhuja Naidoo,
Damir Vareslija,
Arnold D. K Hill,
Leonie Young

摘要

Purpose of Review

In the last decade, poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in the treatment of several cancers, such as breast and ovarian cancer. This article aims to discuss the current uses, limitations, and future directions for PARP inhibitors (PARPis) in the treatment of breast cancer.

Recent Findings

Following the results of the OlympiAD and EMBRACA trials, PARPis were approved in HER2-negative breast cancer with a germline BRCA mutation. We reviewed this class of drugs’ mechanism of action, efficacy, and limitations, as well as further studies that discussed resistance, impaired homologous recombination repair (HRR), and the combination of PARPis with other drugs.

Summary

Improving understanding of HRR, increasing the ability to target resistance, and combining PARPis with other novel agents are continuing to increase the clinical utility of PARPis.